Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-PF-06651600 · 1 trial · 1 indication
Cumulative recovery (%) of radioactivity in urine.
Cumulative recovery (%) of radioactivity in feces
| Arm | Type | Description |
|---|---|---|
| Period A | EXPERIMENTAL | Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600). |
| Period B | EXPERIMENTAL | Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600). |
| Name | Type | Description |
|---|---|---|
| 14C-PF-06651600 | DRUG | Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity |
| 14C-PF-06651600 IV | DRUG | IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity |
| PF-06651600 | DRUG | Oral solution 200mg |
Inclusion Criteria: * Male participants who are healthy as determined by medical evaluation including a detailed medical history, full physical examination, including blood pressure (BP) and pulse rate (PR) measurement, 12 lead ECG, and clinical laboratory tests. * Body mass index (BMI) of 17.5 to ...
14C-PF-06651600 is an investigational small molecule being developed by Pfizer, Inc. It is a radiolabeled form of PF-06651600, used in a Phase 1 clinical trial to study its absorption, distribution, metabolism, and excretion in healthy volunteers. The drug is not approved and remains in clinical development.
14C-PF-06651600 is used in a Phase 1 clinical trial to characterize the absorption, distribution, metabolism, and excretion of the drug, and to evaluate its absolute oral bioavailability and fraction absorbed. The study involves healthy male volunteers in the Netherlands.
14C-PF-06651600 is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
14C-PF-06651600 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The single Phase 1 trial has been completed.
14C-PF-06651600 has one completed Phase 1 clinical trial, identified as NCT03929510. This study, conducted in the Netherlands, enrolled 6 healthy male volunteers aged 18 years and older to evaluate the drug's absorption, distribution, metabolism, excretion, and absolute oral bioavailability.
14C-PF-06651600 is a radiolabeled form of PF-06651600, used in clinical studies to track the drug's behavior in the body. The 14C label allows researchers to characterize the absorption, distribution, metabolism, and excretion of PF-06651600.